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To determine the serotype and genotype of dengue vi-
rus (DENV) in Bhutan, we conducted phylogenetic analyses 
of complete envelope gene sequences. DENV-2 (Cosmo-
politan genotype) predominated in 2004, and DENV-3 (gen-
otype III) predominated in 2005–2006; these viruses were 
imported  from  India.  Primary  dengue  infections  outnum-
bered secondary infections, suggesting recent emergence.
D
engue infections have increased worldwide in recent 
decades. Before 1970, only 9 countries had experi-
enced epidemics of dengue hemorrhagic fever; by 1996, 
this number had increased to 102 (1). Dengue is endemic 
to most of Southeast Asia; high numbers of cases are re-
ported each year in Laos, Cambodia, Vietnam, Singapore, 
and Thailand. Dengue was first reported in Nepal in 2004 
(1). Serologic testing of a group of febrile patients in Nepal 
showed that 8% had immunoglobulin (Ig) M against den-
gue, and a recent report noted 11 serologically confirmed 
dengue cases in 2006 (2,3). The Armed Forces Institute of 
Medical  Sciences  (AFRIMS)  in  Bangkok,  Thailand,  re-
cently confirmed the presence of all 4 dengue serotypes in 
Nepal (4).
In another Himalayan nation, Bhutan, dengue was first 
suspected in the summer of 2004. Bhutan is an extremely 
rugged and mountainous country of 38,394 km2 with an 
altitude ranging from 150 m on the southern border with 
India to >7,000 m in the mountains bordering Tibet (on-
line Appendix Figure, available from www.cdc.gov/EID/
content/15/10/1630-appF.htm).  The  dengue  outbreak  re-
sulted in 2,579 cases (5), almost all of which occurred in 
and around Phuntsholing district (2005 census population 
20,537) in southern Bhutan on the border with India. Fifty-
two serum samples from this outbreak were tested by using 
dengue enzyme immunoassay (EIA) at the National Insti-
tute of Communicable Diseases, New Delhi, India. Twelve 
(23%) samples were positive for antidengue IgM. Thirty-
five (67%) of the 52 samples also were tested at Suraksha 
Hospital, Kolkata, India, of which 5 were positive.
Since the initial report in 2004, fewer clinical cases 
were reported from Bhutan in 2005 and 2006; dengue virus 
3 (DENV)-3 was the dominant serotype (5). Although some 
serologic analysis is available, serum samples from Bhutan 
have not been evaluated for dengue by using molecular 
techniques. In particular, circulating DENV in Bhutan has 
not been genetically characterized, so from where and how 
frequently DENV is imported into Bhutan are unclear.
The Study
Acute-phase blood samples were collected from per-
sons with suspected dengue in and around Phuntsholing 
during 3 periods in 2004–2006 (June 15–August 2, 2004; 
September 8–December 2, 2005; and July 19–November 
30, 2006). All samples were collected from hospitalized 
patients in whom dengue infection was diagnosed on the 
basis of clinical signs and symptoms. Convalescent-phase 
samples were not available. Because all samples were col-
lected by the Bhutan Ministry of Health as part of a public 
health effort, the study did not require institutional review 
board–approved human-use protocol.
A total of 168 samples (53 from 2004, 19 from 2005, 
and 96 from 2006) were delivered to AFRIMS for confir-
matory dengue testing. Samples were tested by using re-
verse transcription–PCR/nested PCR modified from pub-
lished methods (6) and the in-house dengue IgM/IgG EIA 
(7). In addition, the complete envelope (E) gene was se-
quenced for samples that were dengue positive by PCR. 
Two DENV-2–positive samples from 2004 and 19 DENV-
3–positive  samples  from  2005–2006  underwent  E  gene 
sequencing. Sequencing also was attempted on additional 
PCR-positive samples but was not successful because of 
insufficient genetic material. All dengue E gene sequences 
from the study have been submitted to GenBank and as-
signed accession nos. FJ606692–FJ606712.
The E gene sequences generated here were combined 
with homologous sequences from 262 isolates of DENV-2 
(total data set of 264 sequences, 1,485 nt) and 245 isolates 
of DENV-3 (total data set of 264 sequences, 1,479 nt), rep-
resenting the full phylogenetic spectrum of these viruses 
in humans. Maximum-likelihood (ML) phylogenetic trees 
were estimated for both datasets using the method imple-
mented in the PAUP* package (8). The general time revers-
ible + I + Γ4 model of nucleotide substitution was the best 
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fit to DENV-2 and DENV-4 as determined by MODELT-
EST (9). A neighbor-joining bootstrap resampling analysis 
(1,000 replications) also was performed to assess support for 
specific nodes, again by using the ML substitution model.
A total of 168 samples from persons suspected to have 
dengue were tested at AFRIMS. DENV infection was con-
firmed by PCR or EIA for 34 (64%) of 53 samples from 
2004, 12 (63%) of 19 samples from 2005, and 57 (59%) 
of 96 samples from 2006 (combined 103 [61%] of 168 
positive). PCR testing showed 7 samples from 2004 were 
DENV-2; 4 samples from 2005 were DENV-3; and from 
2006, 40 were DENV-3 and 1 was DENV-1 (combined 52 
[31%] of 168 PCR positive).
Serologic  testing  indicated  that  28  samples  from 
2004 were positive for dengue by EIA; 15 were primary 
infections, and 13 were secondary infections according to 
published criteria (7). Ten samples from 2005 were EIA 
positive; 8 were primary infections, and 2 were secondary 
infections. Thirty-nine samples from 2006 were EIA posi-
tive; 23 were primary infections, and 16 were secondary 
infections (Table).
Clinical information for these dengue-positive samples 
was limited. However, mean age of the 103 patients with 
laboratory-confirmed  dengue  was  31  years  (32  years  in 
2004, 28 years in 2005, and 30 years in 2006) (range 2–69 
years). Mean age of the 46 patients with primary dengue 
infection was 29 years; that of the 31 patients with second-
ary dengue infections was 32 years.
Phylogenetic analysis of complete E gene sequences 
indicated that the 2 DENV-2 isolates sampled in 2004 fell 
into the Cosmopolitan genotype, which is widely distrib-
uted throughout the tropical and subtropical world (Figure 
1). These viruses were closely related to those sampled in 
a similar period in the Indian subcontinent (India and Sri 
Lanka), suggesting these DENV-2 isolates were imported 
into Bhutan from the Indian subcontinent. A remarkably 
similar picture was seen for DENV-3 (Figure 2). The 19 
DENV-3 isolates sampled from 2005 and 2006 clustered 
closely within viral genotype III, which is found in Afri-
ca, the Western Hemisphere, and the Indian subcontinent. 
Again, the DENV-3 phylogeny is compatible with the mi-
gration of this virus northward through India to Bhutan.
Conclusions
Our genetic characterization of DENV in Bhutan dem-
onstrates that at least 3 DENV serotypes have circulated 
there. The E gene sequence data for the 2 DENV-2 strains 
from 2004 and the 19 DENV-3 strains from 2005 and 2006 
indicate that the DENV strains in Bhutan are similar to 
those circulating regionally and thus were most likely in-
troduced (or reintroduced) from neighboring areas. That 
such emergence in Bhutan has occurred only recently is 
further supported by the observation of more primary than 
secondary dengue infections for all 3 years, as well as the 
relatively advanced mean age of patients.
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Table. Laboratory-confirmed dengue cases, Bhutan, 2004–2006* 
Dengue cases  PCR serologic results 
Year  Primary  Secondary  Positive Negative
2004 15 13 (1 DENV-2)  6 (DENV-2)  19
2005 8 (2 DENV-3)  2 2 (DENV-3)  7
2006 23 (13 DENV-3)  16 (11 DENV-3)  17 (16 DENV-3, 1 DENV-1)  40
*DENV, dengue virus. 
Figure 1. A) Maximum likelihood phylogenetic tree of 264 complete 
envelope gene sequences of dengue virus serotype 2 (DENV-2). 
The different genotypes of DENV-2 and the isolates from Bhutan 
(red) are indicated. Scale bar indicates number of substitutions per 
site. B) Magnification of the part of the phylogeny where the Bhutan 
sequences (red) fall. The tree is midpoint rooted for clarity only, 
and all horizontal branch lengths are drawn to a scale of nucleotide 
substitutions per site. Bootstrap support values are shown for key 
nodes only. of Virology at the Armed Forces Research Institute of Medical   
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Figure 2. A) Maximum-likelihood phylogenetic tree of 264 complete 
envelope gene sequences of dengue virus serotype 3 (DENV-3). 
The different genotypes of DENV-3 and the isolates from Bhutan 
(red) are indicated. Scale bar indicates number of substitutions per 
site. B) Magnification of the part of the phylogeny where the Bhutan 
sequences (red) fall. The tree is midpoint rooted for clarity only, 
and all horizontal branch lengths are drawn to a scale of nucleotide 
substitutions per site. Bootstrap support values are shown for key 
nodes only.
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